At RSNA 2025, Dr. Talissa Altes, the Chair of the Radiology Department at the University of Missouri describes her past research and what she most looks forward to in her field in the coming time.
Her focus on chronic conditions in young patients makes issues of dose totals over time and the repeated administration of contrast agent a particularly important focus.
Currently Dr. Altes is eagerly awaiting the expected clearance of Bayer's reduced gadolinium content contrast agent Gadoquatrane. She expects this to open up new opportunities within her adolescent patients.
"The contrast agent was developed for the age group from 0 to 17 years. The youngest study participants were four weeks old. We generally administer doses based on weight. We try to avoid gadolinium in very young newborns, but sometimes it is essential for clarifying acute problems. In such cases, a stable contrast agent with a low dosage is particularly valuable."
